by Kole Krieger | Apr 3, 2025 | News
Full Article Here Today, Lumen Bioscience reported that its investigational oral biologic, LMN-201, achieved a 100% clinical cure rate of C difficile infection (CDI) in the sentinel cohort (Part A) of its RePreve clinical trial. All patients (21/21; 95% confidence...
by Kole Krieger | Apr 2, 2025 | Press Release
Strong potential to disrupt market for treatment of C. diff infections RePreve Trial main cohort now recruiting Seattle, WA – April 3, 2025 – In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results...
by Kole Krieger | Nov 7, 2024 | News
New technology and innovation may help turn the corner on antibiotic resistance. The antibiotic resistance crisis poses a threat to modern medicine. Antibiotic-resistant infections have become alarmingly common, and experts warn that if nothing is done we could face a...
by Kole Krieger | Aug 6, 2024 | News, Uncategorized
View on website A biotechnology company has re-invented how biologic drugs are invented by using the patented technology to use the food algae spirulina to deliver therapeutic proteins. The technology has unlimited potential for developing biologic drugs for highly...
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases